Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection

Internal Medicine
Akira KawanoKyushu University Liver Disease Study (KULDS) Group

Abstract

There is little information regarding the incidence of bacterial infections as an adverse effect of telaprevir (TVR)-based triple therapy. This study was performed in order to evaluate the baseline and on-treatment predictors of bacterial infections in patients treated with TVR-based triple therapy. This multicenter study evaluated 430 patients with chronic hepatitis C who received 12 weeks of TVR in combination with 24 weeks of pegylated interferon α2b plus ribavirin. The occurrence of a bacterial infection during anti-viral treatment was defined as the onset of local or systemic inflammation as a result of pathogenic bacteria. Bacterial infections occurred in 21 of the 430 (4.9%) patients during TVR-based triple therapy. Among these subjects, 71.4% (15 of 21) experienced bacterial infections during the initial eight weeks of treatment. Urinary tract infections were the most frequent infection, observed in 2.8% of cases (12 of 430). The rate of urinary tract infection among women (11 of 215, 5.1%) was significantly higher than that observed among men (1 of 215, 0.5%) (p<0.0001). According to a multivariable logistic regression analysis, the only significant independent predictor was the pretreatment serum albumin level (p=0.00...Continue Reading

References

May 1, 1994·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P SimmondsD S Chen
Nov 26, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·C NiederauD Häussinger
Mar 5, 2004·Annals of Internal Medicine·Stephanos J HadziyannisUNKNOWN PEGASYS International Study Group
Apr 21, 2007·Journal of Gastroenterology and Hepatology·Makoto KubokiTakahiro Sakai
Nov 21, 2007·Internal Medicine·Yasuji AraseHiromitsu Kumada
May 1, 2009·The New England Journal of Medicine·John G McHutchisonUNKNOWN PROVE1 Study Team
May 1, 2009·The New England Journal of Medicine·Christophe HézodeUNKNOWN PROVE2 Study Team
Jul 25, 2009·The New England Journal of Medicine·John G McHutchisonUNKNOWN IDEAL Study Team
Apr 9, 2010·The New England Journal of Medicine·John G McHutchisonUNKNOWN PROVE3 Study Team
Jun 22, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Timothy R MorganUNKNOWN HALT-C Trial Group
Jun 24, 2011·The New England Journal of Medicine·Ira M JacobsonUNKNOWN ADVANCE Study Team
Jun 24, 2011·The New England Journal of Medicine·Stefan ZeuzemUNKNOWN REALIZE Study Team
Sep 16, 2011·The New England Journal of Medicine·Kenneth E ShermanUNKNOWN ILLUMINATE Study Team
Nov 3, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Andrew J MuirNathalie Adda
Apr 2, 2013·Journal of Hepatology·Norihiro FurusyoUNKNOWN Kyushu University Liver Disease Study (KULDS) Group
May 28, 2013·Journal of Hepatology·Eiichi OgawaUNKNOWN Kyushu University Liver Disease Study (KULDS) Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.